📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding PBH

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	36.7K	$2.2M	0.00%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Cautious ~ Volatile 4 quarters analysed

Q1 2026

Mixed

concrete actions to address the eye care supply shortfall, including the Pillar5 acquisition and new suppliers. Despite the miss, they highlighted strengths like record free cash flow and gross margin expansion.

Q2 2026

Confident Specific

Management expressed confidence in exceeding Q2 expectations, reiterated full-year guidance with specific numbers (e.g., revenue $1.1B-$1.115B, EPS $4.54-$4.58), and detailed supply chain improvements for Clear Eyes. Language such as 'feel good about the performance' and 'well-positioned' supports a confident, specific tone.

Q3 2026

Mixed

Management expressed confidence in their diversified business model and strategic actions (e.g., Pillar5 acquisition, supply improvements) using phrases like 'solid results', 'successfully managed through', and 'we have confidence in our core business', but also acknowledged significant uncertainty with 'challenging consumer backdrop', 'volatile environment', and 'it's hard to predict' when asked about headwind duration.

Q4 2026 latest

Cautious

Management acknowledged a 'challenging fourth quarter that fell short of expectations' and cited 'difficult consumer environment', 'delayed shipments', and 'production shutdowns'. However, they expressed confidence in returning to organic growth in fiscal 2027 and highlighted a strong free cash flow profile and pending acquisitions as positive catalysts.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is slightly weakened in the near term due to persistent eye care supply disruptions that caused a Q4 miss and will weigh on H1 fiscal 2027. However, management provided a credible plan to ramp production in H2, and the pending acquisitions of Breathe Right and LaCorium Health add high-margin, growing brands that can boost revenue and EPS. The strong free cash flow generation ($250M+ expected) and commitment to debt reduction provide a cushion. Key watch items for next quarter: (1) eye care shipment trajectory, particularly whether production improvements at Pillar5 materialize on schedule, (2) the closing and initial integration of Breathe Right, and (3) any further inflation impacts on margins. If eye care recovery slips again, the thesis weakens further; if acquisitions close smoothly and eye care improves, the long-term outlook remains attractive.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Cautious ~ Volatile 4 quarters Full tone analysis in Intelligence →

📊 MIXED Prestige Consumer Healthcare targets FY2027 revenue $1.1B-$1.12B, 1-3% organic growth.

Revenue & Profitability

Q4 FY2026 revenue was $281.6 million, down 5% year-over-year. Full-year revenue declined approximately 4% organically. Adjusted EPS was $4.38 for the year, down from $4.52. Free cash flow reached $246.4 million, up 1.3%. For FY2027, management expects revenue of $1.1-$1.12 billion and adjusted EPS of $4.42-$4.51.

Outlook

Management views the consumer environment as 'difficult' with persistent inflation and geopolitical conflicts (Middle East). They expect a return to organic growth in FY2027, driven by eye care supply recovery in the back half and solid consumption across the portfolio. Headwinds include eye care supply volatility and shipping disruptions, while tailwinds include e-commerce growth and innovation.

Growth Drivers

Key growth levers include: GI franchise (Dramamine, Fleet, Hydralyte) all grew in FY2026; e-commerce delivered double-digit consumption growth and reached 18% penetration; new product launches (Fleet Mini Enema, Compound W Skin Tag Remover, new Dramamine forms); and eye care capacity expansion. International OTC is expected to return to ~5% organic growth in FY2027.

Balance Sheet & CapEx

Fiscal 2027 capital expenditure is guided at approximately $25 million, representing 1%-3% of sales even after including Pillar5. The company invested $110 million in long-term eye care manufacturing capabilities during FY2026. Ongoing investments are directed at improving Pillar5 output and high-speed line upgrades.

Margins

Adjusted gross margin was 55.6% in FY2026, flat year-over-year, and expected to remain similar in FY2027. Advertising and marketing spend was 13.7% of sales, guided at over 13% for FY2027. G&A is expected at 10.5% of sales for the full year. EBITDA margins are maintained in the low-30s range, supported by cost-saving initiatives and surgical pricing.

Key Risks

Key risks flagged by management include: continued eye care supply constraints and production volatility (Pillar5 ramp-up delays), global conflict and Middle East shipping disruptions, consumer spending pressure, inflationary cost headwinds (especially oil-related), and execution risk from integrating two major acquisitions simultaneously. The Q1 FY2027 guide assumes flat eye care shipments.

Generated by AI · Q4 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q1 2027 Q1 2027 2026-08-06

Q1 revenue grew 6.5% year-over-year, driven by strong GI and skincare brands, with record free cash flow and successful integration of Breathe Right and LaCorium acquisitions. Fiscal 2027 guidance was raised, with acquisitions expected to add ~$190 million in revenue and boost EPS.

Q4 2026 Q4 2026 2026-05-14

Fiscal 2026 saw a 4% revenue decline due to eye care supply issues and global disruptions, but GI and women's health brands performed well. Fiscal 2027 guidance anticipates 1%-3% organic growth, stable margins, and strong free cash flow, with pending acquisitions expected to drive future growth.

Q3 2026 Q3 2026 2026-02-05

Q3 revenue declined 2.4% year-over-year due to Clear Eyes supply constraints, but strong e-commerce and diversified channels offset some headwinds. Free cash flow rose 13% year-to-date, enabling the Pillar5 acquisition and significant share repurchases. Fiscal 2026 guidance was narrowed, with continued improvement in eye care supply expected.

Q2 2026 Q2 2026 2025-11-06

Q2 revenue and EPS exceeded expectations despite a 3.4% sales decline, driven by timing factors and strong e-commerce growth. Full-year guidance was reiterated, with improved Clear Eyes supply expected in the second half and continued robust free cash flow supporting share repurchases and M&A.

Q1 2026 Q1 2026 2025-08-07

Q1 revenue declined 6.6% year-over-year due to eye care supply issues and retail order timing, but gross margin expanded and EPS rose 6%. The company expects supply recovery in the second half, maintains strong free cash flow guidance, and is acquiring Pillar5 to secure long-term eye care supply.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.